Skip to content
Austin Top 50
Author:
CONNECTA Therapeutics
CONNECTA Therapeutics Initiates Phase IIa Clinical Trial of CTH120, a First-in-Class Neuroplasticity Modulator, in Fragile X Syndrome
June 10, 2026